Building on our recent successes with licencing PromarkerD into the USA and Mexico, Proteomics International is pleased to provide a market update on our diagnostics development pipeline. This employs the same pioneering technology that created PromarkerD.
The Promarker pipeline is targeting other chronic diseases to identify potential markers for new diagnostic tests. Preliminary results are promising for endometriosis and infections due to the Giardia parasite.
